Patents by Inventor Mark Winderlich

Mark Winderlich has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Combinations and uses thereof
    Patent number: 12194095
    Abstract: The present disclosure describes a pharmaceutical combination of an anti-CD19 antibody and a phosphoinositide 3-kinase inhibitor for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia and/or acute lymphoblastic leukemia.
    Type: Grant
    Filed: December 8, 2021
    Date of Patent: January 14, 2025
    Assignee: Incyte Corporation
    Inventors: Jan Endell, Mark Winderlich, Rainer Boxhammer
  • COMBINATIONS AND USES THEREOF
    Publication number: 20240424012
    Abstract: The present disclosure describes a pharmaceutical combination of an anti-CD19 antibody and a purine analog for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia and/or acute lymphoblastic leukemia.
    Type: Application
    Filed: February 20, 2024
    Publication date: December 26, 2024
    Inventors: Jutta Amersdorffer, Stefan Steidl, Mark Winderlich, Susanne Krohn, Lisa Rojkjaer
  • COMBINATIONS AND USES THEREOF
    Publication number: 20240366756
    Abstract: The present disclosure describes a pharmaceutical combination of an anti-CD19 antibody and a nitrogen mustard for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia and/or acute lymphoblastic leukemia.
    Type: Application
    Filed: January 12, 2024
    Publication date: November 7, 2024
    Inventors: Jutta AMERSDORFFER, Stefan STEIDL, Mark WINDERLICH, Susanne WIEGEL, Lisa ROJKJAER
  • COMBINATION OF AN ANTI-CD19 ANTIBODY AND A BRUTON'S TYROSINE KINASE INHIBITOR AND USES THEREOF
    Publication number: 20240009196
    Abstract: The present disclsoure describes a pharmaceutical combination of an anti-CD19 antibody and a Bruton's tyrosine kinase (BTK) inhibitor and its use for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia and/or acute lymphoblastic leukemia.
    Type: Application
    Filed: February 1, 2023
    Publication date: January 11, 2024
    Inventors: Jan ENDELL, Rainer BOXHAMMER, Mark WINDERLICH
  • METHODS FOR PREDICTING THERAPEUTIC BENEFIT OF ANTI-CD19 THERAPY IN PATIENTS
    Publication number: 20220283166
    Abstract: The present disclosure is directed to identifying characteristics and biomarkers in patients that benefit from treatment with an anti-CD19 antibody.
    Type: Application
    Filed: May 25, 2022
    Publication date: September 8, 2022
    Inventors: Jan ENDELL, Mark WINDERLICH, Rainer BOXHAMMER
  • ANTI-CD19 THERAPY IN PATIENTS HAVING A LIMITED NUMBER OF NK CELLS
    Publication number: 20220242952
    Abstract: The present disclosure provides characteristics and biomarkers in patients that benefit from treatment with anti-CD19 antibodies (MOR00208, XmAb5574).
    Type: Application
    Filed: May 4, 2020
    Publication date: August 4, 2022
    Inventors: Christian KUFFER, Guenter FINGERLE-ROWSON, Mark WINDERLICH, Jan ENDELL
  • COMBINATIONS AND USES THEREOF
    Publication number: 20220088197
    Abstract: The present disclosure describes a pharmaceutical combination of an anti-CD19 antibody and a phosphoinositide 3-kinase inhibitor for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia and/or acute lymphoblastic leukemia.
    Type: Application
    Filed: December 8, 2021
    Publication date: March 24, 2022
    Inventors: Jan ENDELL, Mark WINDERLICH, Rainer BOXHAMMER
  • Combinations and uses thereof
    Patent number: 11224654
    Abstract: The present disclosure describes a pharmaceutical combination of an anti-CD19 antibody and a phosphoinositide 3-kinase inhibitor for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia and/or acute lymphoblastic leukemia.
    Type: Grant
    Filed: August 18, 2016
    Date of Patent: January 18, 2022
    Assignee: MORPHOSYS AG
    Inventors: Jan Endell, Mark Winderlich, Rainer Boxhammer
  • TREATMENT PARADIGM FOR AN ANTI-CD19 ANTIBODY AND VENETOCLAX COMBINATION TREATMENT
    Publication number: 20210292410
    Abstract: The instant invention describes pharmaceutical compositions and dosing regimens comprising seviteronel and/or dexamethasone, and methods of treating diseases, disorders or symptoms thereof.
    Type: Application
    Filed: May 30, 2018
    Publication date: September 23, 2021
    Inventors: Peter Kelemen, Michael Schwarz, Mark Winderlich, Steffen Heeger, Dominika Weinelt
  • COMBINATIONS AND USES THEREOF
    Publication number: 20200353077
    Abstract: The present disclosure describes a pharmaceutical combination of an anti-CD19 antibody and a nitrogen mustard for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia and/or acute lymphoblastic leukemia.
    Type: Application
    Filed: April 3, 2020
    Publication date: November 12, 2020
    Inventors: Jutta AMERSDORFFER, Stefan STEIDL, Mark WINDERLICH, Susanne KROHN, Lisa ROJKJAER
  • COMBINATIONS AND USES THEREOF
    Publication number: 20200352975
    Abstract: The present disclosure describes a pharmaceutical combination of an anti-CD19 antibody and a purine analog for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia and/or acute lymphoblastic leukemia.
    Type: Application
    Filed: April 3, 2020
    Publication date: November 12, 2020
    Inventors: Jutta AMERSDORFFER, Stefan STEIDL, Mark WINDERLICH, Susanne KROHN, Lisa ROJKJAER
  • COMBINATION OF AN ANTI-CD19 ANTIBODY AND A BRUTON'S TYROSINE KINASE INHIBITOR AND USES THEREOF
    Publication number: 20200206228
    Abstract: The present disclosure describes a pharmaceutical combination of an anti-CD19 antibody and a Bruton's tyrosine kinase (BTK) inhibitor and its use for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia and/or acute lymphoblastic leukemia.
    Type: Application
    Filed: March 2, 2020
    Publication date: July 2, 2020
    Inventors: Jan ENDELL, Rainer BOXHAMMER, Mark WINDERLICH
  • Combination of an anti-CD19 antibody and a Bruton's tyrosine kinase inhibitor and uses thereof
    Patent number: 10617691
    Abstract: The present disclosure describes a pharmaceutical combination of an anti-CD19 antibody and a Bruton's tyrosine kinase (BTK) inhibitor for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia and/or acute lymphoblastic leukemia.
    Type: Grant
    Filed: May 25, 2016
    Date of Patent: April 14, 2020
    Assignee: MORPHOSYS AG
    Inventors: Jan Endell, Rainer Boxhammer, Mark Winderlich
  • METHODS FOR PREDICTING THERAPEUTIC BENEFIT OF ANTI-CD19 THERAPY IN PATIENTS
    Publication number: 20190195879
    Abstract: The present disclosure is directed to a method of identifying a subject having chronic lymphocytic leukemia (CLL), non-Hodgkin's lymphoma (NHL), small lymphocytic lymphoma (SLL) or acute lymphoblastic leukemia (ALL) that is responsive to treatment with an anti-CD19 antibody, said method comprising: a) providing a blood sample obtained from said subject prior to treatment with said anti-CD19 antibody, b) determining the level of at least one biomarker in said sample selected from the group consisting of: i) peripheral NK cell count, and ii) CD16 expression levels on peripheral NK cells, c) comparing the level of said at least one biomarker in said sample to a predetermined cut off level, wherein levels of said at least one biomarker at or above the predetermined cut off level is indicative of a subject who would benefit from treatment with an anti-CD19 antibody.
    Type: Application
    Filed: May 30, 2017
    Publication date: June 27, 2019
    Inventors: Jan Endell, Mark Winderlich, Rainer Boxhammer
  • Method for the treament of multiple myeloma or non-hodgkins lymphoma with anti-CD38 antibody in combination with thalidomine, lenalidomids, or pomalidomide
    Patent number: 10308722
    Abstract: The present disclosure is directed to a method of treating multiple myeloma or non-hodgkins lymphoma with a pharmaceutical composition comprising an anti-CD38 antibody in combination with thalidomide, lenalidomide, or pomalidomide.
    Type: Grant
    Filed: August 7, 2017
    Date of Patent: June 4, 2019
    Assignee: MORPHOSYS AG
    Inventors: Lisa Rojkjaer, Rainer Boxhammer, Jan Endell, Mark Winderlich, Christofer Samuelsson
  • COMBINATIONS AND USES THEREOF
    Publication number: 20180228893
    Abstract: The present disclosure describes a pharmaceutical combination of an anti-CD19 antibody and a phosphoinositide 3-kinase inhibitor for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia and/or acute lymphoblastic leukemia.
    Type: Application
    Filed: August 18, 2016
    Publication date: August 16, 2018
    Inventors: Jan Endell, Mark Winderlich, Rainer Boxhammer
  • COMBINATION OF AN ANTI-CD19 ANTIBODY AND A BRUTON'S TYROSINE KINASE INHIBITOR AND USES THEREOF
    Publication number: 20180153892
    Abstract: The present disclosure describes a pharmaceutical combination of an anti-CD19 antibody and a Bruton's tyrosine kinase (BTK) inhibitor for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia and/or acute lymphoblastic leukemia.
    Type: Application
    Filed: May 25, 2016
    Publication date: June 7, 2018
    Inventors: Jan Endell, Rainer Boxhammer, Mark Winderlich
  • METHOD FOR THE TREATMENT OF MULTIPLE MYELOMA OR NON-HODGKINS LYMPHOMA WITH ANTI-CD38 ANTIBODY AND BORTEZOMIB OR CARFILZOMIB
    Publication number: 20180022823
    Abstract: The present disclosure describes a pharmaceutical combination of an anti-CD38 antibody and lenalidomide and a pharmaceutical combination of an anti-CD38 antibody and bortezomib.
    Type: Application
    Filed: August 7, 2017
    Publication date: January 25, 2018
    Inventors: LISA ROJKJAER, RAINER BOXHAMMER, JAN ENDELL, MARK WINDERLICH, CHRISTOFER SAMUELSSON
  • Method for the treatment of multiple myeloma or non-Hodgkins lymphoma with anti-CD38 antibody and bortezomib or carfilzomib
    Patent number: 9765152
    Abstract: A method of treating multiple myeloma or non-hodgkins lymphoma with a pharmaceutical composition comprising an anti-CD38 antibody and bortezomib or carfilzomib is disclosed.
    Type: Grant
    Filed: February 5, 2016
    Date of Patent: September 19, 2017
    Assignee: MORPHOSYS AG
    Inventors: Lisa Rojkjaer, Rainer Boxhammer, Jan Endell, Mark Winderlich, Christofer Samuelsson
  • Anti-CD38 Antibody and Lenalidomide or Bortezomib for the Treatment of Multipe Myeloma and NHL
    Publication number: 20160222127
    Abstract: The present disclosure describes a pharmaceutical combination of an anti-CD38 antibody and lenalidomide and a pharmaceutical combination of an anti-CD38 antibody and bortezomib.
    Type: Application
    Filed: February 5, 2016
    Publication date: August 4, 2016
    Inventors: Lisa Rojkjaer, Rainer Boxhammer, Jan Endell, Mark Winderlich, Christofer Samuelsson